Incidence and Risk Factors of Cholinergic Syndromes Induced by FOLFIRINOX in Advanced Pancreatic Adenocarcinoma

Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)
doi 10.5649/jjphcs.44.403
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Japanese Society of Pharmaceutical Health Care and Sciences

Related search

Single Nucleotide Polymorphisms and Risk Factors Predictive of Pancreatic Adenocarcinoma

Cancer Cell & Microenvironment
2016English

NeoadjuvantNab-paclitaxel and Gemcitabine in Borderline Resectable or Locally Advanced Unresectable Pancreatic Adenocarcinoma in Patients Who Are Ineligible for FOLFIRINOX

Anticancer Research
MedicineCancer ResearchOncology
2018English

FOLFIRINOX in Patients With Peritoneal Carcinomatosis From Pancreatic Adenocarcinoma: A Retrospective Study

Current Oncology
Oncology
2019English

A Patient-Level Meta-Analysis of FOLFIRINOX for Locally Advanced Pancreatic Cancer

HPB
HepatologyGastroenterology
2016English

Hemorrhage After Major Pancreatic Resection: Incidence, Risk Factors, Management, and Outcome

HPB
HepatologyGastroenterology
2016English

Resectability After Neoadjuvant FOLFIRINOX in Locally Advanced Pancreatic Cancer: A Single-Center Experience

HPB
HepatologyGastroenterology
2016English

Very Early Onset Pancreatic Adenocarcinoma - Clinical Presentation, Risk Factors and Therapeutic Options

Chirurgia (Bucharest, Romania : 1990)
Surgery
2018English

The Benefits of Modified FOLFIRINOX for Advanced Pancreatic Cancer and Its Induced Adverse Events: A Systematic Review and Meta-Analysis

Scientific Reports
Multidisciplinary
2018English

Nationwide Trends in Incidence, Treatment and Survival of Pancreatic Ductal Adenocarcinoma

European Journal of Cancer
Cancer ResearchOncology
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy